Drug Detail

Drug Name Osimertinib
Trade Name Tagrisso
Synonyms AZD9291
Drug Descriptions

Tagrisso (osimertinib) is a third-generation EGFR inhibitor that selectively binds mutant forms of the EGF receptor, inhibiting downstream signaling and potentially reducing cell proliferation and growth in EGFR overexpressing tumors (NCI Drug Dictionary). Tagrisso (osimertinib) is FDA-approved for use in patients with non-small cell lung cancer harboring EGFR exon 19 deletions, L858R, or T790M (FDA.gov).

DrugClasses EGFR Inhibitor 3rd gen 15

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
Bevacizumab + Osimertinib
Carboplatin + Etoposide + Osimertinib
BKM120 + Osimertinib
AZD9291 + MEDI4736
Dacomitinib + Osimertinib Vizimpro (dacomitinib) is a second-generation EGFR inhibitor and pan-HER inhibitor that inhibits HER2 and multiple EGFR subtypes including EGFR T790M, resulting in decreased proliferation and increased apoptosis in EGFR-expressing and HER2-expressing tumor cells (PMID: 22761403, PMID: 18606718). Vizimpro (dacomitinib) is FDA approved for use in patients with metastatic non-small cell lung cancer with EGFR exon 19 deletion or L858R mutation as first-line treatment (FDA.gov).
Necitumumab + Osimertinib
DS-1205b + Osimertinib
Osimertinib + Selumetinib
Crizotinib + Osimertinib
Imatinib mesylate + Osimertinib
Osimertinib + TAK-632
Oleclumab + Osimertinib
Dasatinib + Osimertinib
Osimertinib + Bosutinib + PF-573328
Osimertinib + Rifampin
Cisplatin + Etoposide + Osimertinib
Osimertinib Tagrisso (osimertinib) is a third-generation EGFR inhibitor that selectively binds mutant forms of the EGF receptor, inhibiting downstream signaling and potentially reducing cell proliferation and growth in EGFR overexpressing tumors (NCI Drug Dictionary). Tagrisso (osimertinib) is FDA-approved for use in patients with non-small cell lung cancer harboring EGFR exon 19 deletions, L858R, or T790M (FDA.gov).
BLU-667 + Osimertinib
Osimertinib + Ramucirumab
G1T38 + Osimertinib
Osimertinib + Saracatinib
AZD9291 + JNJ-61186372
INCB039110 + Osimertinib
DS-1205c + Osimertinib
JQ1 + Osimertinib
Osimertinib + Savolitinib
Gefitinib + Osimertinib
GSK2334470 + Osimertinib
Cabozantinib + Osimertinib
AZD9291 + MLN0128
Osimertinib + PF-573328 + Saracatinib
Navitoclax + Osimertinib
Osimertinib + Simvastatin
Alectinib + Osimertinib
Cetuximab + Osimertinib